We’ve noticed for a while now that trials involving immunotherapies have not just standard adverse events reported, but also immune related adverse events (irAEs).  We saw these articulately in combination trials at ASCO earlier this month.

Most of these have involved colitis, hepatitis, pneumonitis and such like. If the signs and symptoms are picked up early through careful monitoring and education, these can be more easily managed and controlled.

What about auto-immune diseases?

Is there a risk of auto-immune disease with long term use usage of checkpoint blockade, especially in situations where patients may be treated until progression, which could be a long time if the patient is one of the lucky ones who get a durable complete response?

In today’s post we take a look at these issues. To learn more, subscribers can log in.

This content is restricted to subscribers

Posted by